BCR-ABL, EGFR, and ALK/ROS1 Kinase Inhibitors

Imatinib was the first BCR-ABL tyrosine kinase inhibitor and remains the prototype of targeted cancer therapy. It binds the adenosine triphosphate-binding site of BCR-ABL in its inactive conformation, blocking phosphorylation of downstream signaling proteins. Imatinib also inhibits the KIT (stem cell factor receptor) kinase, making it effective in gastrointestinal stromal tumors driven by activating KIT mutations.

In chronic myeloid leukemia, response is assessed in three stages: complete hematologic response (normal blood counts), complete cytogenetic response (no Philadelphia chromosome-positive cells on bone marrow cytogenetics), and major molecular response (a 3-log reduction in BCR-ABL transcript levels by reverse transcription polymerase chain reaction). Most patients in chronic-phase disease achieve complete cytogenetic response and major molecular response on imatinib, but approximately one-third eventually develop resistance or intolerance.

The most clinically important resistance mechanism is the T315I point mutation in the BCR-ABL kinase domain, sometimes called the gatekeeper mutation. It eliminates a hydrogen bond critical for imatinib binding and adds steric hindrance, conferring resistance to all first- and second-generation tyrosine kinase inhibitors. Recognizing the T315I mutation is essential because it defines which agents remain active.

Other resistance mutations affect the P-loop (glycine-250 to glutamate, tyrosine-253 to histidine, glutamate-255 to lysine), the contact residues (phenylalanine-317 to leucine), and the activation loop (histidine-396 to arginine). BCR-ABL-independent mechanisms include gene amplification and activation of alternative pathways such as the RAS and SRC kinase cascades.

Dasatinib binds both the active and inactive conformations of BCR-ABL and is approximately 325-fold more potent than imatinib. It also potently inhibits SRC family kinases. Key adverse effects include pleural effusion (requiring dose interruption in severe cases) and pulmonary arterial hypertension with long-term use. Dasatinib is also active against most imatinib-resistant BCR-ABL mutations except T315I.

Nilotinib is highly selective for BCR-ABL in its inactive conformation. Its most important adverse effects are QTc prolongation, which requires baseline electrocardiogram and electrolyte monitoring, and a metabolic profile including hyperglycemia and hyperlipidemia. Peripheral arterial occlusive disease is a recognized long-term risk, especially in patients with pre-existing cardiovascular risk factors.

Bosutinib inhibits BCR-ABL and SRC family kinases and has a predominantly gastrointestinal adverse effect profile — diarrhea occurs in the majority of patients and is the leading cause of dose modification. It is minimally active against KIT and PDGFR (platelet-derived growth factor receptor), giving it a different safety profile from imatinib.

Ponatinib was designed specifically to overcome T315I resistance. It is a pan-BCR-ABL inhibitor active against native BCR-ABL and all known resistance mutations including T315I. Its use is limited by serious cardiovascular toxicity — arterial occlusive events (myocardial infarction, stroke, peripheral arterial disease) occur in a substantial proportion of patients, and it carries a boxed warning for this risk. It is reserved for T315I-positive disease or failure of two prior tyrosine kinase inhibitors.

Asciminib uses a completely different binding mechanism: it targets the myristoyl pocket of BCR-ABL rather than the adenosine triphosphate-binding site, classifying it as a STAMP inhibitor (specifically targeting the ABL myristoyl pocket). This distinct mechanism allows it to overcome resistance mutations that compromise adenosine triphosphate-site inhibitors, including T315I (with the asciminib 200-mg twice-daily dosing). Asciminib has shown superior major molecular response rates compared to bosutinib in patients who have failed two prior tyrosine kinase inhibitors.

The two most common sensitizing mutations are exon 19 deletions (removing a portion of the adenosine triphosphate-binding cleft) and the exon 21 L858R point mutation (leucine-to-arginine substitution at codon 858). Together, these classic mutations account for approximately 85 percent of all EGFR-mutant non-small cell lung cancer. Both mutations increase EGFR kinase activity and confer sensitivity to EGFR tyrosine kinase inhibitors. The exon 20 T790M substitution is an acquired resistance mutation rather than a sensitizing mutation and emerges in about 50 to 60 percent of patients who progress on first- or second-generation agents.

Erlotinib and gefitinib are reversible, competitive inhibitors of the EGFR adenosine triphosphate-binding site. Both are orally administered and metabolized by cytochrome P450 3A4. They produce high response rates (approximately 60 to 70 percent) in patients with classic sensitizing mutations. Median progression-free survival is approximately 9 to 13 months before resistance emerges, typically via T790M mutation. Both agents are now primarily used in settings where osimertinib cannot be given or as components of combination strategies.

Afatinib and dacomitinib are irreversible covalent inhibitors that bind not only EGFR but also the related receptor tyrosine kinases HER2 and HER4 (human epidermal growth factor receptor 2 and 4), making them pan-HER inhibitors. Irreversible binding prolongs receptor inhibition, and these agents are active against some uncommon exon 18 and exon 21 mutations that first-generation agents do not cover well. However, they do not overcome the T790M resistance mutation and produce more severe adverse effects — particularly diarrhea, acneiform rash, and mucositis — compared to first-generation agents.

Osimertinib is an irreversible, mutant-selective EGFR inhibitor that preferentially inhibits T790M-bearing EGFR with a much lower affinity for wild-type EGFR. This selectivity accounts for its improved tolerability compared to earlier generations. Osimertinib is now the preferred first-line agent for metastatic EGFR-mutant non-small cell lung cancer, having demonstrated superior progression-free and overall survival compared to erlotinib or gefitinib in the FLAURA trial (a randomized phase 3 study of osimertinib versus erlotinib or gefitinib as first-line therapy). It also has meaningful CNS (central nervous system) penetration, making it the preferred agent when brain metastases are present.

Resistance to osimertinib is heterogeneous. Unlike first- and second-generation resistance (which is dominated by T790M), osimertinib resistance involves diverse mechanisms including C797S mutation (which prevents covalent binding), MET (mesenchymal-epithelial transition factor receptor) amplification, HER2 amplification, and small cell lung cancer transformation. No single agent has yet demonstrated clear benefit in post-osimertinib resistance, making this an area of active investigation.

Crizotinib was the first approved ALK inhibitor and was originally developed as a MET (mesenchymal-epithelial transition) inhibitor before its ALK activity was recognized. It is active against ALK, ROS1, and MET receptor tyrosine kinases. Crizotinib produces objective response rates above 60 percent in ALK-rearranged non-small cell lung cancer with median progression-free survival of approximately 10 to 11 months. However, resistance invariably develops, most commonly through secondary mutations in the ALK kinase domain (L1196M, C1156Y, G1269A) and through central nervous system relapse due to poor blood-brain barrier penetration.

Adverse effects of crizotinib include visual disturbances (flashes of light and floaters, particularly at transitions between light and dark, due to unknown mechanism), nausea and vomiting, elevated liver enzymes, and peripheral edema. Bradycardia is a recognized adverse effect requiring heart rate monitoring. Crizotinib is primarily metabolized by cytochrome P450 3A4 and is itself a moderate cytochrome P450 3A4 inhibitor.

Alectinib was designed to overcome crizotinib resistance mutations and has superior central nervous system penetration compared to crizotinib. The ALEX trial (a randomized phase 3 study comparing alectinib to crizotinib) demonstrated that alectinib significantly outperformed crizotinib as first-line therapy in ALK-positive non-small cell lung cancer (median progression-free survival approximately 34 versus 11 months), establishing alectinib as the preferred first-line agent in most settings. Alectinib is generally well tolerated; myalgia, edema, and elevated creatine kinase are the most common adverse effects. It does not share crizotinib's visual adverse effects.

Brigatinib is active against a broader spectrum of ALK resistance mutations than alectinib and also has meaningful central nervous system activity. Its characteristic adverse effect is early-onset pulmonary toxicity — shortness of breath and hypoxia occurring within the first week of treatment in approximately 3 to 9 percent of patients; a reduced starting dose with escalation after a week is recommended. Ceritinib was an early second-generation agent but has largely been supplanted by alectinib and brigatinib due to its gastrointestinal toxicity profile.

Lorlatinib is a macrocyclic tyrosine kinase inhibitor with the broadest coverage of ALK resistance mutations and the best central nervous system penetration of the class. It is active against compound mutations (multiple simultaneous mutations in ALK) that develop after treatment with second-generation agents. The CROWN trial (a randomized phase 3 study comparing lorlatinib to crizotinib) demonstrated that lorlatinib improved progression-free survival compared to crizotinib as first-line therapy, with a particularly striking reduction in central nervous system progression. Adverse effects include hypercholesterolemia and hypertriglyceridemia (in most patients, often requiring statin therapy), central nervous system effects (cognitive impairment, mood changes, speech effects), and edema.